<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The 72-kD inducible heat shock protein (HSP72) can attenuate cerebral ischemic injury when overexpressed before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Whether HSP72 overexpression is protective when applied after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> <z:hpo ids='HP_0003674'>onset</z:hpo> is not known, but would have important clinical implications </plain></SENT>
<SENT sid="2" pm="."><plain>Fifty-seven rats underwent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> for 1 hour </plain></SENT>
<SENT sid="3" pm="."><plain>Defective <z:e sem="disease" ids="C0019348" disease_type="Disease or Syndrome" abbrv="">herpes simplex</z:e> <z:mp ids='MP_0001799'>viral</z:mp> (HSV) vectors expressing hsp72 with lacZ as a reporter were delivered 0.5, 2, and 5 hours after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> <z:hpo ids='HP_0003674'>onset</z:hpo> into each striatum </plain></SENT>
<SENT sid="4" pm="."><plain>Control animals received an identical vector containing only lacZ </plain></SENT>
<SENT sid="5" pm="."><plain>Striatal neuron survival at 2 days was improved by 23% and 15% when HSP72 vectors were delayed 0.5 and 2 hours after ischemic <z:hpo ids='HP_0003674'>onset</z:hpo>, respectively ( P &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>However, when delayed by 5 hours, HSP72 overexpression was no longer protective </plain></SENT>
<SENT sid="7" pm="."><plain>This is the first demonstration that HSP72 gene transfer even after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> <z:hpo ids='HP_0003674'>onset</z:hpo> is neuroprotective </plain></SENT>
<SENT sid="8" pm="."><plain>Because expression from these HSV vectors begins 4 to 6 hours after injection, this suggests that the temporal therapeutic window for HSP72 is at least 6 hours after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Future strategies aimed at enhancing HSP72 expression after clinical <z:hpo ids='HP_0001297'>stroke</z:hpo> may be worth pursuing </plain></SENT>
<SENT sid="10" pm="."><plain>The authors suggest that in the future HSP72 may be an effective treatment for <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>